#CARTcells

2 months ago

Great presentation by my colleague Heather Landau on transformative results of BCMA #CARTcells for #amyloidosis #tandem26 @mskcancercenter.bsky.social @mskdeptofmed.bsky.social

7 1 0 0

2 months ago

My @mskcancercenter.bsky.social colleague Dr Roisin E. O'Cearbhaill discussing role of cell therapy at #tandem26 Joint session @astct.bsky.social @sitcancer.bsky.social #tcellrx #cartcells

3 2 0 0

FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases As the first CAR-T treatment for an autoimmune disease dr | As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willi...

2 months ago

FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication.

www.fiercebiotech.com/biotech/fda-...

1 0 0 0

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

2 months ago

Scientists show that engineering #CARTcells to overexpress #CXCR4 restores #CXCL12-guided migration, enhances #tumortracking and #BoneMarrow homing, promotes memory persistence, and improves #antitumor efficacy in #BcellLymphoma and #myeloma.

#STTT: doi.org/10.1038/s413...

2 0 0 0

Feucht & Leibold Lab

@teamjjtueb.bsky.social

3 months ago

CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency - Nature Cancer By performing a CAR-adapted base-editing screen of phosphatidylinositol-3-kinase delta (PI3Kδ, PIK3CD), Bucher et al. identify mutations affecting endogenous PI3K–AKT signaling that enhances CAR T cel...

🚀New paper alert and a great way to start the year for Philip and #TeamJJ!🚀 Our paper on enhancing T cell anti-tumor potency through CAR-adapted PIK3CD base editing is now out in Nature Cancer. For more details visit: www.nature.com/articles/s43...

#TeamJJ #NatureCancer #iFIT #CARTcells

4 0 0 0

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 SHANGHAI,Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted

3 months ago

Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.

buff.ly/SKuRXC9

1 0 0 0

Hamid Mirzaei

@hamidmirzaei81.bsky.social

3 months ago

Excited to share our paper that has been published in the @journalofnucmed.bsky.social
jnm.snmjournals.org/content/earl...
Our findings demonstrate the feasibility of PET-based CAR-T cell tracking in a solid tumor model through selective DOTA-hapten and Thor platform. #cartcells #immunotherapy

1 0 0 0

Roswell Park Comprehensive Cancer Center

@roswellpark.bsky.social

3 months ago

🚨 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗖𝗔𝗥 𝗧-𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆!

Roswell Park researchers have developed IL-36 gamma “armored” CAR T cells that reprogram neutrophils to attack solid tumors.

🔗Read the full press release here: roswellpark.org/newsroom/202...

#CARTCells #RoswellPark

3 1 0 1

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial Kyverna Therapeutics' CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness.

3 months ago

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial.
#CARTCells #Autoimmune disease

2 0 0 0

Melvin Sanicas, MD MSc MBA

@vaccinologist.bsky.social

3 months ago

Researchers at @roswellpark.bsky.social Comprehensive #Cancer Center report in Cancer Cell that IL-36γ–armored #CARTcells can eradicate solid #tumors in preclinical models by reprogramming neutrophils and amplifying innate and adaptive anti #tumor #immunity.

www.linkedin.com/posts/drmelv...

1 0 0 0

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia | NEJM CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of b...

3 months ago

Allogeneic anti-CD7 #CARTCells for relapsing T-ALL eradication prior to hematopoietic allograft!

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia | New England Journal of Medicine buff.ly/7jYX07o

1 0 0 0

3 months ago

#ash25 early results in 4 patients with in vivo BCMA #CARTcells 2/2

0 0 0 0

CSF1R-CAR T cells induce CSF1R signaling and can promote target cell proliferation Chimeric antigen receptor–stimulated responses in target cells may affect target cell clearance by CAR T cells.

3 months ago

Very impressive preliminary results of in vivo BCMA #CARTcells. High expansion of CART, excellent responses with low toxicity without lymphodepletion #ash25 #mmsm 1/2

3 1 1 0

Nick Vitanza

@nickvitanza.bsky.social

4 months ago

Proud to share this elegant work by the very talented Dr. Edward Song on the engineered overexpression of CXCR3 in #CARTcells to drive better trafficking to pediatric brain & spinal tumors (beautiful art by www.katierisvicari.com) #VitanzaLab @seattlechildrens.org

www.nature.com/articles/s41...

3 1 0 0

Nature Medicine

@natmed.nature.com

4 months ago

⚡Our November issue is out! Featuring trials of #CARTcells for #LUPUS, an #ADC for #lungcancer, cardiac #genetherapy, an #ebola #vaccine, discovery of microbial elements in #braintumors, #liquidbiopsies, #newbornscreening, News, Reviews, & more.
https://www.nature.com/nm/volumes/31/issues/11

6 2 1 0

Science Magazine

@science.org

4 months ago

A #ScienceSignaling study examines the activities of ligand-based #CARTcells and shows they induce proliferative signaling events within target cells, a finding that has implications for the design and application of future CAR T cells in the clinic. https://scim.ag/47CxSMB

22 7 0 0

Pitt Department of Immunology

@pitt-immunology.bsky.social

5 months ago

Small-molecule control of CAR T cells - Nature Reviews Chemistry Chimeric antigen receptor (CAR) T cells are a promising and effective cancer therapy but are difficult to regulate once implanted. This Review covers an emerging wave of small-molecule-based systems d...

New in Nature Reviews Chemistry: Jason Lohmueller and colleagues review small-molecule control systems for #CARTCells — addressing toxicity & resistance challenges in #cancer #immunotherapy

Read the article: www.nature.com/articles/s41...

1 0 0 0

Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.

5 months ago

Jennifer Doudna startup launches with $82M to apply new #CRISPR delivery technology to in vivo #CARTCells.

buff.ly/mewzZFL

3 0 0 0